Dr. Maziéres on the Evaluation of Tepotinib Plus Osimertinib in EGFR-mutated NSCLC

Julien Maziéres, MD, PhD, professor of Medicine, University Hospital, researcher, the Claudius Regaud Institute, discusses the evaluation of tepotinib (Tepmetko) plus osimertinib (Tagrisso) in EGFR-mutated non­–small cell lung cancer (NSCLC).

Data from the phase 2 INSIGHT 2 trial (NCT03940703) evaluating the use of tepotinib plus osimertinib in patients with EGFR-mutated, MET-amplified NSCLC were presented at the 2022 ESMO Congress.

The primary end point of the trial was overall response rate (ORR) for patients with of MET amplification confirmed by fluorescence in situ hybridization, Maziéres says, adding that 48 patients had a follow-up of 3 months or more, and 22 patients had a follow-up of 9 months or more. Patients with at least 9 months of follow-up experienced an ORR of 54.5%, and patients with at least 3 months of follow-up achieved an ORR of 45.8%, Maziéres explains.

In patients with MET amplifications confirmed by next-generation sequencing, 16 patients with at least 9 months of follow-up who received tepotinib plus osimertinib had an ORR of 50%, and 23 patients with at least 3 months of follow-up experienced an ORR of 56.5%, Maziéres continues. Twelve patients treated with tepotinib alone had an ORR of 8.3%, highlighting the need for patients to receive the MET inhibitor in combination with osimertinib, Maziéres concludes.